3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
3
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Dermatologic
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
69
Nivolumab
58
Ipilimumab
35
Specimen Handling
32
Magnetic Resonance Spectroscopy
25
Cyclophosphamide
22
Biopsy
18
cemiplimab
14
fludarabine
13
relatlimab
11
binimetinib
11
Opdualag
11
trametinib
10
fludarabine phosphate
10
Radiosurgery
10
CTLA-4 Antigen
10
avelumab
9
lifileucel
8
dabrafenib
8
Radiotherapy
8
atezolizumab
7
aldesleukin
7
Paclitaxel
7
Blood Specimen Collection
7
encorafenib
6
X-Rays
6
Standard of Care
6
Interleukin-2
6
Immunoglobulin G
6
HhAntag691
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genetic Counseling
×
Dermatologic
×
90 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled